Serum biomarker linked to brain atrophy in multiple sclerosis

Serum biomarker linked to brain atrophy in multiple sclerosis

(HealthDay)—Serum neurofilament light chain (sNFL) levels are significantly associated with clinical and neuroimaging outcomes in multiple sclerosis (MS), according to a study published online Aug. 12 in JAMA Neurology.

Ester Cantó, Ph.D., from the University of California in San Francisco, and colleagues conducted a involving 607 patients with MS to examine the potential of sNFL measurements as a biomarker of disease activity and progression. Patients were followed for up to 12 years.

The researchers observed significant correlations for baseline sNFL levels with Expanded Disability Status Scale (EDSS) score, MS subtype, and treatment status. Over time, there was a significant interaction between EDSS worsening and change in levels of sNFL. About 11.6 percent of the variation in brain fraction atrophy at year 10 was associated with baseline sNFL levels alone. Baseline sNFL levels alone correlated with 18 percent of the variance in brain fraction atrophy in multivariable analyses that considered sex, age, and disease duration. Active treatment correlated with lower levels of sNFL after five years' follow-up; compared with platform therapy, high-potency treatments correlated with the greater decreases in sNFL levels (high-potency versus untreated: β, 0.946; high-potency versus platform: β, 0.972).

"Consistent with , sNFL levels at baseline may be associated, albeit modestly, with future brain fraction atrophy as early as one year after sampling," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.


Explore further

Model explores how statins alter multiple sclerosis outcomes

More information: Abstract/Full Text (subscription or payment may be required)
Journal information: Archives of Neurology

Copyright © 2019 HealthDay. All rights reserved.

Citation: Serum biomarker linked to brain atrophy in multiple sclerosis (2019, September 11) retrieved 22 September 2019 from https://medicalxpress.com/news/2019-09-serum-biomarker-linked-brain-atrophy.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
3 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more